.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Argus Health
Moodys
Healthtrust
Daiichi Sankyo
Express Scripts
Merck
Deloitte
Cipla
Dow

Generated: September 22, 2017

DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and sixty-seven approved drugs.

There are thirty-one US patents protecting TEVA PHARM drugs and there have been two Paragraph IV challenges on TEVA PHARM drugs in the past three years. There are thirty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and six patent family members on TEVA PHARM drugs in thirty-eight countries.

Summary for Applicant: Teva Pharm

Patents:31
Tradenames:223
Ingredients:216
NDAs:267
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm
AIRDUO RESPICLICK
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Usa
ATOMOXETINE HYDROCHLORIDE
atomoxetine hydrochloride
CAPSULE;ORAL079022-005May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-002Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Usa
ATAZANAVIR SULFATE
atazanavir sulfate
CAPSULE;ORAL091673-004Apr 22, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
SELFEMRA
fluoxetine hydrochloride
TABLET;ORAL200151-001Feb 3, 2014AB1RXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharm
ARMONAIR RESPICLICK
fluticasone propionate
POWDER;INHALATION208798-001Jan 27, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL040472-003Sep 30, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
NADOLOL
nadolol
TABLET;ORAL074368-003Aug 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
CARBAMAZEPINE
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL078592-001Sep 20, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
OLANZAPINE
olanzapine
TABLET;ORAL076000-005Oct 24, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
omacetaxine mepesuccinate
for Injection3.5 mg/vial
SYNRIBO
10/26/2016
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
2/26/2014
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
1/29/2014
cyclobenzaprine hydrochloride
Extended-release Capsule15 mg and 30 mg
AMRIX
8/11/2008

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,108,010Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
9,526,851Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
6,655,381 Pre-metered dose magazine for breath-actuated dry powder inhaler► Subscribe
8,877,245Modified release dosage forms of skeletal muscle relaxants► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
9,174,013Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,737,674Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,526,850Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Pharm Drugs

Country Document Number Estimated Expiration
Portugal2405749► Subscribe
Austria506094► Subscribe
European Patent Office1294420► Subscribe
South Korea101628934► Subscribe
Australia7011301► Subscribe
Germany69923768► Subscribe
European Patent Office2514463► Subscribe
Denmark2177223► Subscribe
South Korea20160038057► Subscribe
Canada2779347► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0103Belgium► SubscribePRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
C/GB06/008United Kingdom► SubscribePRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
/1998Austria► SubscribePRODUCT NAME: RIZATRIPTAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE RIZATRIPTANBENZOAT; NAT. REGISTRATION NO/DATE: 1-22636 - 1-22639 19980709; FIRST REGISTRATION: NL 21815 - 21818 19980211
/2013Austria► SubscribePRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
C/GB98/043United Kingdom► SubscribePRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
C/GB98/027United Kingdom► SubscribePRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203
2016000120Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Dow
Fuji
Deloitte
AstraZeneca
Cantor Fitzgerald
Merck
Covington
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot